We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Study Supports Activity of Gemcitabine in Treatment of Early-Stage Breast Cancer

Oct 1, 2007
Volume: 
21
Issue: 
11
  • Breast Cancer, Breast Cancer

Gemcitabine (Gemzar), which is approved in combination with paclitaxel (Taxol) in the first-line, postsurgical treatment of metastatic breast cancer, was the subject of a study presented at the 43rd annual meeting of the American Society of Clinical Oncology (ASCO), with encouraging results in the presurgical treatment of breast cancer.

Promising Regimen

Results of the study showed that adding gemcitabine to the current standard-of-care treatment was a promising regimen for patients with stage II/III breast cancer. The phase II investigation (abstract #595) evaluated the addition of gemcitabine to the current standard-of-care of epirubicin (Ellence) and cyclophosphamide followed by paclitaxel in patients with stage II/III breast cancer. The treatment schedule was a dose-dense sequential neoadjuvant (presurgical) chemotherapy combination, meaning that the combination was administered at shorter intervals between treatments.

Results showed a promising regimen in terms of pathologic complete response (pCR). In addition, patients who tested positive for the HER2 gene also were given trastuzumab (Herceptin) and demonstrated additional response.

More About the ASCO Trial

The trial enrolled stage II/III breast cancer patients (with a median age of 45 years), including inflammatory tumors, a type of breast cancer that causes the breast to swell, redden, and feel warm. Of the 73 patients enrolled in the investigation, 42 (57.5%) were classified as T2, 12 (16.5%) as T3, and 19 (26%) as T4, which included 13 patients with inflammatory tumors. A biopsy was performed before treatment for the biomarker component of the study.

Patients received a first sequence of epirubicin and cyclophosphamide (90/600 mg/m2) for three cycles followed by a second sequence of paclitaxel and gemcitabine (150/2,500 mg/m2) for six cycles. Treatment was administered on day 1, every 2 weeks, with growth factor support. HER2-positive patients (20 patients, 27.3%), were given trastuzumab (2 mg/kg with a loading dose of 4 mg/kg) concomitantly. Afterward, the patients underwent surgery, radiotherapy, and adjuvant hormonal therapy according to individual institutional practice.

All patients from the study showed a response to the regimen. Of the entire study group, 27 patients (36.9%) achieved a pCR, with 50% representation from the HER2-positive patients who also were given trastuzumab. A total of 47 patients (64.4%) underwent conservative surgery.

The grade 3/4 hematologic toxicities were leukopenia in six patients (9%); neutropenia in eight patients (12%), and; anemia in one (2%). Nausea (13%) and vomiting (15%) were the most frequent grade 3/4 nonhematologic toxicities. Asymptomatic decrease in cardiac ejection fraction was observed in one patient treated with trastuzumab, with subsequent normalization.

Aggressive Research Plan

Pages

  • 1
  • 2
  • next ›
  • last »

Related Articles

  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms
  • COUNTERPOINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
  • POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.